Know Cancer

or
forgot password

Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma


Phase 1
18 Years
70 Years
Not Enrolling
Both
Multiple Myeloma, Plasmocytoma

Thank you

Trial Information

Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma


Inclusion Criteria:



- multiple myeloma

- stage I (Salmon & Durie)

- no cytoreductive pre-treatment

Exclusion Criteria:

- myeloma stages II-III

- asecretory disease

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Specific T-cell proliferation/cytokine secretion

Safety Issue:

No

Principal Investigator

Susanne Gretzinger, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital Dresden

Authority:

Germany: not applicable since not necessary

Study ID:

MyelomVak

NCT ID:

NCT00988312

Start Date:

March 2002

Completion Date:

March 2004

Related Keywords:

  • Multiple Myeloma
  • Plasmocytoma
  • dendritic cells (DC)
  • idiotype (Id)
  • immunotherapy
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma

Name

Location